Rilvegostomig

AstraZeneca is testing rilvegostomig, a bispecific antibody that blocks both PD-1 and TIGIT on immune cells, combined with gemcitabine/cisplatin as post-surgery treatment for biliary tract cancer in the Phase 3 ARTEMIDE-Biliary01 trial [1]. Biliary tract cancer (BTC) recurs in 60-70% of patients after resection, and no immunotherapy has yet proven effective in the adjuvant setting. This trial tests whether dual checkpoint blockade after surgery can extend disease-free survival in a cancer with few good options.

Rilvegostomig is a novel compound with no approved indications anywhere in the world. ARTEMIDE-Biliary01 (NCT06109779) is a Phase 3, randomized, double-blind trial comparing rilvegostomig plus gemcitabine/cisplatin against placebo plus the same chemotherapy in BTC patients who have undergone curative-intent surgery [1]. AstraZeneca has not announced any FDA designations for this indication. The bigger picture: AstraZeneca is running a parallel trial, ARTEMIDE-Biliary02 (NCT07221253), testing rilvegostomig or durvalumab plus chemotherapy as first-line treatment in advanced BTC with 1,100 patients and an overall survival primary endpoint in PD-L1-positive patients [4]. This dual-program strategy signals AstraZeneca's intent to position rilvegostomig as the successor to durvalumab across the full BTC treatment sequence. The adjuvant trial likely started enrollment in late 2023, and given the time needed to accrue disease-free survival events in a post-surgical population, a primary readout before 2027 seems unlikely. Real-world data on durvalumab plus gem/cis continues to accumulate, setting the benchmark against which rilvegostomig will ultimately be measured [5][6].

Rilvegostomig blocks two inhibitory receptors on immune cells simultaneously: PD-1 and TIGIT. PD-1 is the better-known immune brake. Tumors press it by displaying PD-L1 on their surface, telling T cells to back off. Blocking PD-1 or PD-L1 is the basis of durvalumab, pembrolizumab, and nivolumab. TIGIT is a second brake on T cells and NK cells (natural killer cells, the immune system's rapid-response force). TIGIT competes with an activating receptor called CD226 for the same binding partners - CD155 and CD112 - on tumor cells. When TIGIT wins, immune activity drops. The rationale for a bispecific: release just one brake and the other can compensate. Single-agent TIGIT inhibitors have mostly failed - Roche's tiragolumab missed its primary endpoint in the SKYSCRAPER-01 lung cancer trial [7], and other TIGIT programs have disappointed. The bispecific format puts both blocking functions on one molecule, forcing simultaneous PD-1 and TIGIT blockade on the same immune cell. Whether this co-engagement matters more than giving two separate antibodies is unproven but biologically plausible. In BTC, we already know that blocking the PD-1/PD-L1 axis works. TOPAZ-1 showed that adding durvalumab to gem/cis extended overall survival in advanced disease [2]. The question rilvegostomig poses: can adding TIGIT blockade on top of PD-1 blockade squeeze out more benefit, and does that translate to the adjuvant setting where the target is invisible micro-metastatic disease left behind after surgery?

ARTEMIDE-Biliary01 (NCT06109779) randomizes patients with resected biliary tract cancer - intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer - to rilvegostomig plus investigator's choice of gemcitabine/cisplatin or placebo plus the same chemotherapy [1]. It is double-blind and placebo-controlled. The primary endpoint is disease-free survival (DFS). The adjuvant BTC space is thin. BILCAP established capecitabine as a modest standard after resection (HR 0.75 for DFS) [3], and the ACTICCA-1 trial tested adjuvant gem/cis versus observation [8]. No immunotherapy has an adjuvant BTC approval. The "investigator's choice" chemotherapy design allows flexibility in dosing regimens but introduces some heterogeneity across study sites, which could complicate interpretation if the treatment effect is modest. One structural challenge: only 20-30% of BTC patients are candidates for curative-intent surgery, making enrollment inherently slow. Adjuvant trials also need time for recurrence events to accumulate before the data matures. AstraZeneca's global footprint helps here, enabling recruitment across high-incidence regions in Southeast Asia where cholangiocarcinoma is far more common than in the West. The comparator arm of placebo plus chemo is reasonable given current practice, though some centers now use capecitabine-based regimens after BILCAP, creating potential divergence between trial control arms and real-world adjuvant standards.

The model gives this drug a 15% chance of eventually being approved. That figure starts from a historical approval rate of about 48% for Phase 3 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The sponsor's strong track record of getting drugs approved pushes the estimate up, while heavier-than-usual blinding, weak earlier-phase results, and a randomized design pull it down. The remaining factors are close to average for this stage, leaving the final estimate well below where it started.

Worth tracking, not yet actionable. ARTEMIDE-Biliary01 will not read out for years, and the trial that matters more for understanding rilvegostomig's value is ARTEMIDE-Biliary02, the first-line advanced BTC trial comparing rilvegostomig to durvalumab with 1,100 patients and an OS primary endpoint [4]. That data arrives first and answers the more fundamental question: does dual PD-1/TIGIT blockade actually beat single PD-L1 blockade in BTC? The decision tree is straightforward. If ARTEMIDE-Biliary02 shows rilvegostomig plus chemo beats durvalumab plus chemo in first-line advanced BTC, the adjuvant trial's odds rise substantially because the mechanism is validated and the adjuvant hypothesis becomes plausible. If ARTEMIDE-Biliary02 shows no advantage over durvalumab, the rationale for a longer, harder adjuvant trial weakens considerably. For AstraZeneca, this is lifecycle management. Durvalumab faces growing competition from pembrolizumab after KEYNOTE-966 [9] and emerging checkpoint-chemotherapy combinations. Rilvegostomig needs to be demonstrably better than durvalumab to justify the franchise transition. Real-world data already shows durvalumab plus gem/cis performing in line with trial expectations outside clinical studies [5][6], so the commercial benchmark is established. Check back when ARTEMIDE-Biliary02 reports interim data, most likely in late 2026 or 2027. Until then, the adjuvant trial is a supporting player in AstraZeneca's BTC strategy, not the headline.